Skip to main content
ORIC logo

ORIC · Oric Pharmaceuticals, Inc.

Track ORIC — free
$12.86 +0.12 (+0.94%) At close · Sep 4
Market Cap
$1.32B
Shares
103.65M

ORIC metrics

52 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.86
Market cap
$1.32B

Price action

19 metrics
Price change (1W)
-2.9%
Price change (30D)
-0.5%
Price change (3M)
+71.5%
Price change (6M)
-6.2%
Price change (YTD)
+57.2%
Price change (1Y)
+19.4%
Trailing year
Price change (5Y)
-44.1%
52-week high
$14.65
52-week low
$7.48
Change from 52-week high
-12.2%
Change from 52-week low
+72.0%
Annualized volatility
86.4%
Beta
1.5
RSI (14D)
48.9
Price vs SMA 50
+5.6%
Price vs SMA 200
+20.6%
Avg volume (3M)
1.56M
Relative volume
0.6
Average dollar volume
$17.35M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
103.65M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
P / book
3.5
reciprocal yield 28.9%
FCF yield
-8.5%
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-10.6%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2022-03-21

Profitability

9 metrics
Gross margin
Operating margin
Trailing 12 months
Net margin
Gross profit (TTM)
Operating profit (TTM)
−$156.14M
Net income (TTM)
−$140.35M
Trailing 12 months
Diluted EPS (TTM)
$-1.30
FCF margin
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$-45.40

Growth

11 metrics
Revenue growth YoY
Year over year
Net income growth YoY
Revenue (TTM)
Trailing 12 months
EPS growth YoY
Shares change YoY
+38.3%
Year over year · more shares
Revenue CAGR (3Y)
Revenue CAGR (5Y)
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-36.8%
Return on assets
-34.7%
Debt / equity
Current ratio
13.2
EBITDA (TTM)
Free cash flow (TTM)
−$112.26M
Quick ratio
13.2
Interest coverage
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Cash & equivalents
$37.48M
Total assets
$404.69M
Total debt
$10.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$111.64M
Capital expenditures (TTM)
$620,000
R&D (TTM)
$122.36M
SG&A (TTM)
Stock compensation (TTM)
$25.90M
R&D / revenue
Stock compensation / revenue

Ownership (13F)

3 metrics
13F filers
181
13F filer change QoQ
-1
Institutional ownership
119.7%

Short interest

3 metrics
Short interest
17.7%
Latest settlement · 11.0 days to cover
Days to cover
11.0d
Short-squeeze score
85 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.21M
Insider-sentiment score

Risk flags

1 metrics
Going concern
Key facts CIK 1796280 CUSIP 68622P109 13F (30d) 158 filings 158 filers Visit website Investor relations